| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 76 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 76 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 76 |
| 3 | METHOTREXATE | 52 |
| 4 | METHOTREXATE SODIUM | 52 |
| 5 | ETOPOSIDE | 45 |
| 6 | CYTARABINE | 34 |
| 7 | CISPLATIN | 31 |
| 8 | VINCRISTINE SULFATE | 28 |
| 9 | MERCAPTOPURINE | 24 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DACTINOMYCIN | 13 | 0.0059 |
| 1 | MITOMYCIN | 8 | 0.0022 |
| 2 | VINBLASTINE SULFATE | 4 | 0.0020 |
| 3 | BLEOMYCIN SULFATE | 16 | 0.0015 |
| 4 | MERCAPTOPURINE | 24 | 0.0014 |
| 5 | MITOXANTRONE HYDROCHLORIDE | 8 | 0.0013 |
| 6 | DACARBAZINE | 9 | 0.0012 |
| 7 | VINCRISTINE SULFATE | 28 | 0.0009 |
| 8 | ETOPOSIDE | 45 | 0.0006 |
| 9 | CYTARABINE | 34 | 0.0006 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 94 |
| 1 | Folate Analog Metabolic Inhibitor [EPC] | 52 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 48 |
| 3 | Topoisomerase Inhibitor [EPC] | 45 |
| 4 | Platinum-based Drug [EPC] | 38 |
| 5 | Corticosteroid [EPC] | 33 |
| 6 | Microtubule Inhibitor [EPC] | 14 |
| 7 | Actinomycin [EPC] | 13 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 10 |
| 9 | Antimetabolite [EPC] | 8 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Actinomycin [EPC] | 13 | 0.0059 |
| 1 | Topoisomerase Inhibitor [EPC] | 45 | 0.0006 |
| 2 | Alkylating Drug [EPC] | 94 | 0.0004 |
| 3 | CD33-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 48 | 0.0002 |
| 5 | Platinum-based Drug [EPC] | 38 | 0.0001 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 52 | 0.0001 |
| 7 | Microtubule Inhibitor [EPC] | 14 | 0.0001 |
| 8 | CD52-directed Cytolytic Antibody [EPC] | 1 | 0.0001 |
| 9 | Purine Antimetabolite [EPC] | 4 | 0.0000 |